当前位置: X-MOL 学术Lancet Diabetes Endocrinol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cardiorenal risk reduction guidance in diabetes: can we reach consensus?
The Lancet Diabetes & Endocrinology ( IF 44.5 ) Pub Date : 2020-03-11 , DOI: 10.1016/s2213-8587(20)30062-0
Naveed Sattar 1 , John Jv McMurray 1 , Alice Yy Cheng 2
Affiliation  

Since the early 2000s, the number of diabetes drugs has more than doubled and over 20 cardiovascular or renal outcome trials have been completed. The new evidence has accrued at such a rapid rate that many health-care professionals are struggling to keep up. Guideline and consensus committees are tasked with summarising the evidence in a manner that is balanced, easily digestible, and practical.

中文翻译:

降低糖尿病的心血管风险指南:我们能否达成共识?

自2000年代初以来,糖尿病药物的数量增加了一倍以上,并且已经完成了20多次心血管或肾脏结局试验。新的证据以如此之快的速度积累,以至于许多医疗保健专业人员都在努力跟上。指导委员会和共识委员会的任务是以平衡,易于消化和实用的方式总结证据。
更新日期:2020-03-12
down
wechat
bug